mRNA 2.0 Immunotherapy for Cancer
Time: 9:00 am
day: Day Two
Details:
- Improvements in innate immunogenicity of mRNA therapeutics can expand their
therapeutic window - Cancer ribosomes provide a novel opportunity for the design of onco-selective
mRNAs - Stealth, onco-selective, and oncolytic mRNAs can induce tumor regression in
syngeneic mouse models resistant to check-point inhibitors
